Product Description
Triclosan (TCS) is an antimicrobial used so ubiquitously that 75% of the US population is likely exposed to this compound via consumer goods and personal care products. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29182464/)
Mechanisms of Action: Fatty Acid Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Oral,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Bangladesh | Brazil | Canada | Chile | Colombia | Dominican Republic | Ecuador | Germany | Greece | Hong Kong | India | Ireland | Israel | Italy | Malaysia | Mexico | New Zealand | Pakistan | Peru | Portugal | Saudi Arabia | South Africa | Spain | Switzerland | Taiwan | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Colgate Palmolive
Company Location: NEW YORK NY 10022
Company CEO: Noel R. Wallace
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Dental Plaque|Gingivitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CRO-2023-11-PG-DWN-CA-BGS | P3 |
Active, not recruiting |
Dental Plaque|Gingivitis |
2024-04-16 |
38% |
| CRO-2023-11-PG-DWN-CA-BGS | P3 |
Active, not recruiting |
Dental Plaque|Gingivitis |
2024-04-16 |
38% |